- Trials with a EudraCT protocol (34)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (10)
34 result(s) found for: Arterial Embolization.
Displaying page 1 of 2.
EudraCT Number: 2019-001920-36 | Sponsor Protocol Number: NIMAO/2018-01/JF-01 | Start Date*: 2020-12-03 | |||||||||||
Sponsor Name:CHU de NIMES | |||||||||||||
Full Title: Phase II a study to evaluate the safety, tolerability, distribution and dose effect of neoadjuvant doxorubicin arterial embolization in patients with prostate cancer at high risk of recurrence befo... | |||||||||||||
Medical condition: patients with high-risk prostate cancer with a Gleason score of 9-10 on biopsy,multimodal treatment radical prostatectomy validated in CPR, managed in Hospital of Nîmes. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004859-22 | Sponsor Protocol Number: UF9888 | Start Date*: 2018-04-12 | |||||||||||
Sponsor Name:University Hospital of Monptellier | |||||||||||||
Full Title: Treatment of hepatocellular carcinoma on child cirrhosis A/B7 by intra-arterial injection of a Lipiodol and Idarubicin emulsion : a multicentric single-arm phase II study | |||||||||||||
Medical condition: The research hypothesis is that hepatic locoregional treatment without embolization, using a more cytotoxic anticancer molecule (Idarubicin) than those conventionally used, would be more effective. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006097-76 | Sponsor Protocol Number: LOTUS | Start Date*: 2013-01-11 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE" | |||||||||||||
Full Title: RANDOMIZED PHASE 3 TRIAL EVALUATING THE EFFICACY OF LOCOREGIONAL TREATMENT WITH TRANSARTERIAL EMBOLIZATION (TAE) FOR LIVER METASTASIS, IN COMBINATION WITH OCTREOTIDE LAR, IN PATIENTS WITH NEUROENDO... | |||||||||||||
Medical condition: PATIENTS WITH NEUROENDOCRINE TUMOR AND INOPERABLE LIVER METASTASIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005931-58 | Sponsor Protocol Number: APHP200043 | Start Date*: 2021-04-02 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: ACTIVE : ACid tranexamic or Terlipressin for Initial emergency treatment of mild to seVere hEmoptysis | ||
Medical condition: Hemoptysis, whatever the cause, with the exception of cystic fibrosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002708-38 | Sponsor Protocol Number: 131313 | Start Date*: 2020-10-26 |
Sponsor Name:Department of Medical Science Gothenburg University | ||
Full Title: Optimized pharmacological treatment for broken heart (takotsubo) syndrome | ||
Medical condition: The medical condition is acute heart failure (Takotsubo syndrome) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000740-25 | Sponsor Protocol Number: RAD-18-TAcE | Start Date*: 2018-09-12 | |||||||||||
Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI | |||||||||||||
Full Title: “TRANSARTERIAL EMBOLIZATION ALONE VERSUS DRUG-ELUTING BEADS CHEMOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA. A RANDOMIZED CONTROLLED TRIAL” | |||||||||||||
Medical condition: Hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000586-33 | Sponsor Protocol Number: 19-PP-15 | Start Date*: 2021-07-21 | |||||||||||
Sponsor Name:CHU de Nice | |||||||||||||
Full Title: Effect of molar sodium lactate infusion on cerebral hemodynamic in patients with severe subarachnoid hemorrhage: a multicenter double-blind randomized controlled study | |||||||||||||
Medical condition: Subarachnoid hemorrhage caused by rupture of cerebral aneurysm | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000270-28 | Sponsor Protocol Number: NL75171.058.20 | Start Date*: 2022-06-30 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: Selective Indocyanine Green Injection of a Segmental Hepatic Artery Followed by Near-Infrared Fluorescence Guided Anatomical Liver Resection: A Feasibility Study | ||
Medical condition: Hepatocellular carcinoma, hepatic adenoma, intrahepatic cholangiocarcinoma, colorectal liver metastases | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001599-13 | Sponsor Protocol Number: TNKCAT | Start Date*: 2021-08-13 |
Sponsor Name:Hospital Vall Hebron | ||
Full Title: Tenecteplase Compared to Alteplase for Large Vesel Oclusion patients before Thrombectomy | ||
Medical condition: Acute Ischaemic Stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001014-32 | Sponsor Protocol Number: 2006-001014-32 | Start Date*: 2006-07-28 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA | |||||||||||||
Full Title: PHASE II STUDY OF BAY 43-9006 IN PATIENTS WITH ADVANCED CHOLANGIOCELLULAR CARCINOMA | |||||||||||||
Medical condition: ᄋ Patients should have proven primary CCC according to one of the following criteria: o Histological evidence of CCC on a biopsy specimen. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002162-40 | Sponsor Protocol Number: 2021-004 | Start Date*: 2022-02-21 |
Sponsor Name:Haaglanden Medisch Centrum | ||
Full Title: IBIS: A single-centre, phase II study to evaluate the safety, tolerability and pharmacokinetics of 2-IminoBiotin in acute Ischemic Stroke due to large vessel occlusion | ||
Medical condition: Acute ischemic stroke due to proximal large vessel occlusion | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001287-10 | Sponsor Protocol Number: NBK241/2/2022 | Start Date*: 2023-09-22 | |||||||||||
Sponsor Name:Gdański Uniwersytet Medyczny | |||||||||||||
Full Title: Treatment of acute ischemic stroke due to occlusion of a large vessel by mechanical thrombectomy in patients with unknown onset or not meeting the criteria for CT eligibility (ASPECTS <6) based on ... | |||||||||||||
Medical condition: acute ischemic stroke caused by occlusion of a large vessel | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007629-32 | Sponsor Protocol Number: TAC101-202 | Start Date*: 2009-02-19 | |||||||||||
Sponsor Name:Taiho Pharma USA, Inc. | |||||||||||||
Full Title: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, INTERNATIONAL, MULTICENTER STUDY OF ORAL TAC 101 AS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA WHO RECEIVED SO... | |||||||||||||
Medical condition: Advanced Hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) FR (Completed) BE (Completed) IT (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008715-26 | Sponsor Protocol Number: CA182037 | Start Date*: 2009-08-05 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carci... | |||||||||||||
Medical condition: intermediate stage hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001466-21 | Sponsor Protocol Number: 61364 | Start Date*: 2017-10-19 | |||||||||||
Sponsor Name:Erasmus MC University Medical Center | |||||||||||||
Full Title: Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands. The effect of periprocedural MEDication: heparin, antiplatelet agents, both or neither. | |||||||||||||
Medical condition: Acute ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001770-40 | Sponsor Protocol Number: 11546 | Start Date*: 2005-06-03 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized controlled study of BAY 43-9006 in combination with doxorubicin versus doxorubicin in patients with advanced hepatocellular carcinoma. | |||||||||||||
Medical condition: advanced hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012570-13 | Sponsor Protocol Number: BAY73-4506/14596 | Start Date*: 2009-08-25 | |||||||||||
Sponsor Name:Bayer HealthCare AG, D51368 Leverkusen | |||||||||||||
Full Title: An uncontrolled open label multicenter phase II safety study of BAY 73-4506 in patients with hepatocellular carcinoma (HCC) | |||||||||||||
Medical condition: Hepatocellular carcinoma, in patients who have failed (experienced radiological progression) previous treatment cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006637-14 | Sponsor Protocol Number: A6181170 | Start Date*: 2008-09-01 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, 10017 | |||||||||||||
Full Title: A MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SUNITINIB MALATE VERSUS SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA | |||||||||||||
Medical condition: Advanced Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) FR (Completed) DE (Prematurely Ended) BE (Completed) IT (Prematurely Ended) SE (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000311-25 | Sponsor Protocol Number: BAY86-9766/16553 | Start Date*: 2013-10-17 |
Sponsor Name:Bayer Healthcare AG | ||
Full Title: A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC) | ||
Medical condition: KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) BE (Completed) AT (Completed) GB (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003308-10 | Sponsor Protocol Number: ARQ197-A-U303 | Start Date*: 2012-12-20 | |||||||||||
Sponsor Name:DAIICHI SANKIO DEVELOPMENT LIMITED | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy | |||||||||||||
Medical condition: MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) NL (Completed) ES (Completed) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.